title: CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow.
abstract: Autologous bone marrow transplants (BMTs) can repopulate the hematologic system of patients treated with marrow-ablative chemotherapy and/or radiotherapy. However, treatment of the bone marrow graft to eliminate residual tumor cells prior to reinfusion can delay the return of peripheral blood elements, presumably from damage to or loss of hematopoietic stem cells responsible for hematologic recovery. To develop a model predictive of hematologic recovery, we studied the progenitor cell contents of 4-hydroperoxycyclophosphamide (100 micrograms/mL)-purged bone marrow grafts of 40 consecutive patients undergoing autologous BMT at this center. Granulocyte-macrophage colonies (CFU-GM) were grown from all grafts after treatment with this chemotherapeutic agent, but erythroid (BFU-E) and mixed (CFU-GEMM) colonies were grown from only 44% and 33% of the grafts respectively. The recovery of CFU-GM after purging ranged from 0.07% to 23%. The logarithm of CFU-GM content of the treated grafts was linearly correlated with the time to recovery of peripheral blood leukocytes (r = -0.80), neutrophils (r = -0.79), reticulocytes (r = -0.60), and platelets (r = -0.66). The CFU-GM content of purged autologous bone marrow grafts may reflect the hematopoietic stem cell content of the grafts and thus predict the rate of hematologic recovery in patients undergoing autologous BMT.
authors.forename: S D
authors.initials: SD
authors.lastname: Rowley
authors.forename: M
authors.initials: M
authors.lastname: Zuehlsdorf
authors.forename: H G
authors.initials: HG
authors.lastname: Braine
authors.forename: O M
authors.initials: OM
authors.lastname: Colvin
authors.forename: J
authors.initials: J
authors.lastname: Davis
authors.forename: R J
authors.initials: RJ
authors.lastname: Jones
authors.forename: R
authors.initials: R
authors.lastname: Saral
authors.forename: L L
authors.initials: LL
authors.lastname: Sensenbrenner
authors.forename: A
authors.initials: A
authors.lastname: Yeager
authors.forename: G W
authors.initials: GW
authors.lastname: Santos
mesh_terms: D000293:Adolescent; D000328:Adult; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003114:Colony-Forming Units Assay; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006098:Granulocytes / Q000166:cytology* / Q000187:drug effects; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000628:therapy; D007958:Leukocyte Count; D008264:Macrophages / Q000166:cytology* / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D014182:Transplantation, Autologous
chemical_list: D003520:Cyclophosphamide; C011272:perfosfamide